Agenus(AGEN.US)

Last Updated 19:00:00 ET
longbridge loading

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer | AGEN Stock News

StockTitan·
US
AGEN
-2.22%
US
IBBQ
+0.07%
US
SBIO
-1.24%
StockTitan·
US
AGEN
-2.22%
US
IBBQ
+0.07%
US
SBIO
-1.24%

Agenus Buy Rating Reaffirmed as Late-Stage Strategy Advances; $23 Price Target Maintained

Tip Ranks·
US
AGEN
-2.22%
Tip Ranks·
US
AGEN
-2.22%

Agenus shares are trading lower. The company reported its Q1 financial results.

benzinga_article·
US
AGEN
-2.22%
US
IBBQ
+0.07%
US
LABU
-2.35%
benzinga_article·
US
AGEN
-2.22%
US
IBBQ
+0.07%
US
LABU
-2.35%

Agenus | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 33.7 M

Earnings Watch·
US
AGEN
-2.22%
Earnings Watch·
US
AGEN
-2.22%

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development | AGEN Stock News

StockTitan·
US
AGEN
-2.22%
US
SBIO
-1.24%
US
PBE
+0.11%
StockTitan·
US
AGEN
-2.22%
US
SBIO
-1.24%
US
PBE
+0.11%

Agenus Q1 2026 Earnings Preview

businessinsider·
US
AGEN
-2.22%
US
FBT
+0.54%
US
PBE
+0.11%
businessinsider·
US
AGEN
-2.22%
US
FBT
+0.54%
US
PBE
+0.11%

Disrupting Scientific Friction: How Ome Ogbru Uses AI to Free Real Science

Unusual Whales·
US
AGEN
-2.22%
SH
CS精准医
+0.59%
US
INGN
+2.38%
Unusual Whales·
US
AGEN
-2.22%
SH
CS精准医
+0.59%
US
INGN
+2.38%

Agenus (AGEN) Expected to Announce Earnings on Monday

Market Beat·
US
AGEN
-2.22%
US
IBB
+0.10%
US
SBIO
-1.24%
Market Beat·
US
AGEN
-2.22%
US
IBB
+0.10%
US
SBIO
-1.24%
© 2026 Longbridge｜Disclaimer